Brought to you by 
Series A brings in $2.7mm for Vaxart
20 Nov 2007
Executive Summary
Vaxart (developing oral vaccines for infectious diseases) raised $2.7mm in its Series A financing co-led by Quantum Technology Partners and Life Science Angels with Bay Partners and Sand Hill Angels also participating.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Vaccines
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series A brings in $2.7mm for Vaxart
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice